Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis
Biochemical Pharmacology · 2026-01 · 243 · 117459
DOI: 10.1016/j.bcp.2025.117459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-01. Verfasst von Xueqin Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Pyroptosis, Inflammasomes, TOR Serine-Threonine Kinases. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program.
Abstract (Originalsprache)
Pyroptosis is an inflammatory form of programmed cell death primarily driven by activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which triggers caspase-1-dependent cleavage of gasdermin D (GSDMD) and subsequent release of pro-inflammatory cytokines. The mechanistic target of rapamycin (mTOR) signaling pathway has emerged as a critical regulator of pyroptosis, yet its precise role in inflammasome activation remains to be incompletely understood. Here, we report that compound CD25, a novel non-covalent small-molecule inhibitor, suppresses NLRP3 inflammasome-mediated pyroptosis by targeting both mTORC1 and mTORC2 pathways. Furthermore, CD25 preserved mitochondrial integrity, thereby inhibiting apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization, and blocking GSDMD cleavage and membrane pore formation in macrophages. In murine models of lipopolysaccharide-induced sepsis and acetaminophen-induced acute liver injury, administration of CD25 markedly attenuated immune-mediated inflammatory injury and ameliorated tissue damage. Collectively, these findings highlight mTOR signaling as a promising therapeutic target for modulating NLRP3-dependent pyroptosis in immune-related inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Division of Thyroid Surgery, Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chen…
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: haoyu_ye@scu.edu.cn.
Förderung
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Jiang, X., Zhang, X., Cai, X., Tang, M., Peng, J., Zhang, R., Su, K., Lin, L., Ma, R., Shen, C., Wu, W., & Ye, H. (2026). Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis. Biochemical Pharmacology, 243, 117459. https://doi.org/10.1016/j.bcp.2025.117459
Vancouver
Jiang X, Zhang X, Cai X, Tang M, Peng J, Zhang R, et al. Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis. Biochemical Pharmacology. 2026;243:117459. doi:10.1016/j.bcp.2025.117459
BibTeX
@article{Jiang2026,
author = {Jiang, Xueqin and Zhang, Xinlu and Cai, Xiaoying and Tang, Minghai and Peng, Jing and Zhang, Ruijia and Su, Kaiyue and Lin, Lei and Ma, Rupei and Shen, Caiyun and Wu, Wenshuang and Ye, Haoyu},
title = {Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {243},
pages = {117459},
doi = {10.1016/j.bcp.2025.117459}
}
EUVIMED